Quantitative assessment of the association between three polymorphisms in FAS and FASL gene and breast cancer risk

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3035-3039

  Wang, Zexing ^a   Gu, Jun ^a   Nie, Weiwei ^b   Xu, Jing ^a   Huang, Guichun ^a   Guan, Xiaoxiang ^a,b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; FAS; FASL; Polymorphisms; Risk

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CHINESE; FAS GENE; FASL GENE; GENE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; PRIORITY JOURNAL; PUBLISHING; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; RISK ASSESSMENT; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

ANTIGENS, CD95; BREAST NEOPLASMS; FAS LIGAND PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; RISK;

EID: 84898782525     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1392-9     Document Type: Article

References (23)

1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461-84.
2. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342-8.
3. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997;57(6):1007-12.
4. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, et al. FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res. 2000;60(4):822-8.
5. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer. 2000;89(2):127-32.
6. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63(15):4327-30.
7. Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002;29(6):1183-8.
8. Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases. PloS ONE. 2013;8(1):11.
9. Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 2012;3(3):625-8.
10. Zhang B, Sun T, Xue L, Han X, Lu N, Shi Y, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28(5):1067-73.
11. Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007;28(12):2548-51.
12. Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H. Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004 Oct 6;96(19):1478-9; author reply 1479
13. Berry KJ, Johnston JE, Mielke Jr PW. An alternative measure of effect size for Cochran's Q test for related proportions. Percept Mot Skills. 2007;104(3 Pt 2):1236-42.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-48.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-101.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34.
18. Gutierrez LS, Eliza M, Niven-Fairchild T, Naftolin F, Mor G. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat. 1999;54(3):245-53.
19. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol. 2002;80(2):131-7.
20. Ju ST, Panka DJ, Cui H, Ettinger R. el-Khatib M, Sherr DH et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373(6513):444-8.
21. Tian J, Pan F, Li J, Ma Y, Cen H, Pan HF, et al. Association between the FAS/FASL polymorphisms and gastric cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(3):945-51.
22. Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis. 2009;30(3):487-93.
23. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132-8.